These results suggest that AD808’s sustained-release formulation and targeted delivery minimize systemic MT3 metabolism, enhance blood–brain barrier penetration, improve metal homeostasis regulation, and reduce oxidative damage in AD mice. Here, MT3 is linked to Alzheimer disease.